Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-Thalassemia

Abstract

β-Thalassemia is one of the most common inherited anemias, with no effective cure for most patients. The pathophysiology reflects an imbalance between α-and β-globin chains with an excess of free α-globin chains causing ineffective erythropoiesis and hemolysis. When α-Thalassemia is co-inherited with β-Thalassemia, excess free α-globin chains are reduced significantly ameliorating the clinical severity. Here we demonstrate the use of CRISPR/Cas9 genome editing of primary human hematopoietic stem/progenitor (CD34+) cells to emulate a natural mutation, which deletes the MCS-R2 α-globin enhancer and causes α-Thalassemia. When edited CD34+ cells are differentiated into erythroid cells, we observe the expected reduction in α-globin expression and a correction of the pathologic globin chain imbalance in cells from patients with β-Thalassemia. Xenograft assays show that a proportion of the edited CD34+ cells are long-Term repopulating hematopoietic stem cells, demonstrating the potential of this approach for translation into a therapy for β-Thalassemia.